Latest news with #ADMABiologics
Yahoo
24-06-2025
- Business
- Yahoo
ADMA Biologics (ADMA) Drops 14.7% W/W as 3 Execs Unload Portfolios
ADMA Biologics, Inc. (NASDAQ:ADMA) is one of the . ADMA Biologics fell by 14.7 percent week-on-week, closing Friday at $17.74 versus the $20.81 on June 13, as investors took path from three of its executives' recent disposition of shares in the company. In a regulatory filing, ADMA Biologics, Inc. (NASDAQ:ADMA) President and CEO Adam Grossman sold 21,000 ADMA shares at a price of $20.81 apiece on June 16 for a total value of $437,010. On the same day, he acquired 15,000 shares at a price of $5.4 apiece for a total of $81,000. ADMA Biologics, Inc. (NASDAQ:ADMA) said that the transaction was in line with the Rule 10b5-1 trading plan entered into between Grossman and Fidelity Brokerage Services LLC. The transaction followed sales activities made by the company's chairman, Steven Elms, and founder and vice chairman, Jerrold Grossman. For his part, Elms sold 425,621 of his shares in the company for an aggregate market value of $9.3 million, while Jerrold disposed of 10,000 shares at an aggregate market value of $206,100. An independent distributor in their pharmacy with a range of biopharmaceutical products on display. It is worth noting that ADMA Biologics, Inc.'s (NASDAQ:ADMA) closing price on Friday marked its sixth straight day of decline. While we acknowledge the potential of ADMA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
23-05-2025
- Business
- Yahoo
Exploring High Growth Tech Stocks In The US May 2025
The U.S. market is currently experiencing heightened volatility, with major indices like the Dow Jones and Nasdaq Composite facing declines due to renewed trade tensions following President Trump's recent tariff threats against the EU and Apple. In this environment, identifying high-growth tech stocks requires a focus on companies that demonstrate resilience through innovation and adaptability amidst shifting economic policies and global trade uncertainties. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 26.38% 39.09% ★★★★★★ Ardelyx 20.78% 59.46% ★★★★★★ Travere Therapeutics 26.41% 64.47% ★★★★★★ Blueprint Medicines 21.36% 61.45% ★★★★★★ TG Therapeutics 26.46% 38.75% ★★★★★★ Alnylam Pharmaceuticals 23.65% 61.11% ★★★★★★ AVITA Medical 27.28% 60.66% ★★★★★★ Alkami Technology 20.54% 76.67% ★★★★★★ Ascendis Pharma 35.16% 60.26% ★★★★★★ Lumentum Holdings 21.59% 110.32% ★★★★★★ Click here to see the full list of 237 stocks from our US High Growth Tech and AI Stocks screener. Below we spotlight a couple of our favorites from our exclusive screener. Simply Wall St Growth Rating: ★★★★★☆ Overview: Bit Digital, Inc., along with its subsidiaries, operates in the bitcoin mining industry and has a market capitalization of $502.52 million. Operations: The company is involved in bitcoin mining, focusing on generating revenue through the production of bitcoin. With a market capitalization of $502.52 million, its business model revolves around leveraging its mining operations to capitalize on the cryptocurrency market. Despite recent setbacks, Bit Digital's aggressive expansion into AI infrastructure, highlighted by its new data center in Quebec and a significant partnership with Cerebras Systems, underscores its strategic pivot towards high-growth sectors. This move is particularly notable as the company navigates through a challenging phase marked by a substantial net loss of $57.71 million in Q1 2025 and a sharp revenue drop from the previous year. However, with an expected annual profit growth of 103% and revenue growth forecasts outpacing the market at 34.6%, Bit Digital is positioning itself to capitalize on burgeoning tech trends, albeit amidst financial volatility and shareholder dilution concerns from recent equity offerings. Click here and access our complete health analysis report to understand the dynamics of Bit Digital. Gain insights into Bit Digital's historical performance by reviewing our past performance report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for treating immune deficiencies and infectious diseases globally, with a market cap of $4.80 billion. Operations: ADMA Biologics generates revenue primarily from its ADMA Biomanufacturing segment, which accounts for $449.41 million, and its Plasma Collection Centers contributing $9.83 million. ADMA Biologics has demonstrated robust growth with a 20.8% forecast in annual earnings and an 18.6% increase in revenue per year, outpacing the US market average of 14.3% and 8.6%, respectively. This growth is supported by strategic advancements, such as the FDA-approved yield enhancement process that boosts production by approximately 20%. Additionally, the company's proactive financial strategy is evident from its recent share repurchase program valued at $500 million and upward revisions in revenue expectations to over $625 million by 2026, reflecting strong operational performance and market confidence. Dive into the specifics of ADMA Biologics here with our thorough health report. Evaluate ADMA Biologics' historical performance by accessing our past performance report. Simply Wall St Growth Rating: ★★★★★☆ Overview: Geron Corporation is a commercial-stage biopharmaceutical company dedicated to developing therapeutic products for oncology, with a market capitalization of $853.47 million. Operations: Geron Corporation generates revenue primarily from the development of therapeutic products for oncology, amounting to $116.29 million. The focus on oncology therapeutics defines its business model and revenue stream. Despite Geron's current unprofitability, its revenue is projected to grow at an impressive rate of 35.9% annually, outstripping the US market average of 8.6%. This growth trajectory is underpinned by a significant increase in R&D spending aimed at developing innovative biotech solutions, reflecting a strategic commitment to long-term value creation through scientific advancement. Recent financial results underscore this potential: Q1 2025 revenue surged to $39.6 million from just $0.304 million the previous year, alongside a reduction in net loss from $55.39 million to $19.84 million year-over-year, signaling improving operational efficiency and market adaptation despite ongoing legal challenges and leadership transitions that could influence future performance and investor sentiment. Get an in-depth perspective on Geron's performance by reading our health report here. Explore historical data to track Geron's performance over time in our Past section. Delve into our full catalog of 237 US High Growth Tech and AI Stocks here. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqCM:BTBT NasdaqGM:ADMA and NasdaqGS:GERN. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-05-2025
- Business
- Yahoo
Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings?
ADMA Biologics ADMA is scheduled to report first-quarter 2025 results on May 7, after market close. The Zacks Consensus Estimate for sales and earnings is pegged at $119.1 million and 16 cents per share, respectively. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Earnings estimate for 2025 has increased to 71 cents from 69 cents per share over the past 60 days, and the same for 2026 has improved to 93 cents from 87 cents. Zacks Investment Research Image Source: Zacks Investment Research ADMA's Earnings Surprise History ADMA has a mixed track record. Its earnings beat estimates in three of the trailing four quarters and missed in the remaining one, delivering an average surprise of 32.8%. However, in the previously reported quarter, the company's earnings missed estimates by 6.67%. Zacks Investment Research Image Source: Zacks Investment Research What Our Model Predicts for ADMA Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Earnings ESP for ADMA is 0.00%. The company currently carries a Zacks Rank #2. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Factors Influencing ADMA's Q1 Results ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases. The company's top line currently comprises sales of three FDA-approved products, which are Bivigam (an Intravenous Immune Globulin [IVIG] product to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency disease or PIDD) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus). Asceniv, its lead product, is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies. These antibodies are proteins used by the body's immune system to neutralize microbes, such as bacteria and viruses, and prevent infection and disease. Asceniv is indicated for the treatment of PIDD or inborn errors of immunity in adults and adolescents. It is manufactured using ADMA's unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma with respiratory syncytial virus plasma obtained from donors tested using the company's proprietary microneutralization assay. Increased sales of Asceniv have likely fueled the top line in the first quarter. Gross margin has also likely improved due to a significantly more favorable mix of high margin immunoglobulin (IG) sales.
Yahoo
29-04-2025
- Business
- Yahoo
Why ADMA Biologics, Inc. (ADMA) Surged on Monday
We recently published an article titled . In this article, we are going to take a look at where ADMA Biologics, Inc. (NASDAQ:ADMA) stands against the other stocks. The stock market kicked off the trading week on a mixed note, with two major indices ending in the green, as investors continued to digest more corporate earnings results. Among the bellwether indices, only the Nasdaq ended in the red, dropping 0.10 percent. In contrast, the Dow Jones grew by 0.28 percent and the S&P 500 inched up by 0.06 percent. Meanwhile, 10 companies mirrored a broader market optimism, as investors snapped up shares ahead of their first-quarter earnings performance in the next few days. To come up with the list, we considered only the companies with a $2-billion market capitalization and $5-million trading volume. An independent distributor in their pharmacy with a range of biopharmaceutical products on display. ADMA Biologics, Inc. (NASDAQ:ADMA) soared to a new all-time high on Monday after securing the approval of the Food and Drug Administration (FDA) for its innovative yield enhancement production process. According to the company, the innovative process has demonstrated an ability to increase production yields by approximately 20 percent from the same starting plasma volume. Following the announcement, ADMA Biologics, Inc. (NASDAQ:ADMA) touched a new record high of $25.67 at intraday trading before early profit-taking pulled its price slightly lower to end the day just up by 12.12 percent at $24.51 apiece. 'This approval represents a pivotal milestone for ADMA, unlocking the opportunity for meaningful acceleration in our revenue and earnings trajectory beginning in late 2025 and accelerating further into 2026 and beyond,' said Adam Grossman, president and CEO of ADMA Biologics, Inc. (NASDAQ:ADMA). 'Looking ahead, we are excited to continue to advance our internal R&D platform—further optimizing production capabilities and progressing novel pipeline programs, most notably SG-001, our pre-clinical, investigative hyperimmune globulin targeting S. pneumonia, which exemplifies our commitment to product and process innovation,' he added. Overall ADMA ranks 3rd on our list of the best performing stocks on Monday. While we acknowledge the potential of ADMA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ADMA but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
25-04-2025
- Business
- Yahoo
ADMA Biologics, Inc. (ADMA): Among Takeover Rumors Hedge Funds Are Buying
We recently published a list of In this article, we are going to take a look at where ADMA Biologics, Inc. (NASDAQ:ADMA) stands against other takeover rumor stocks hedge funds are buying. Hedge funds tend to pile up on a stock that gains or is expected to gain positive attention in a market. And what more could ignite such a frenzy of activity other than whispers of potential takeovers? When combined with subtle market signals and insider movements, these rumors can cause investors to purchase the stock. Income-seeking investors usually keep a close eye on such signs and movements to capitalize on emerging opportunities. READ ALSO: In particular, hedge fund managers, using their vast resources and analytical capabilities, are more receptive to such speculative cues and act upon them. Since investors and the rest of the market tend to generate income by closely following their actions, hedge funds hold influential power in market trajectories. The allure of these rumors lies in their potential to generate substantial returns to shareholders. Those companies that become the target of a takeover or are perceived as a target experience a stock value surge in the market, thus attracting further investor interest. To stay ahead of the curve, hedge funds conduct thorough analyses, including financial statement evaluations, industry trend monitoring, and management behavior assessments, to predict the possibility of such events. Such a proactive approach, in addition to giving them an edge over other investors in the market, also contributes to the evolving nature of financial markets. What prompts the takeover rumors? Loads of factors. In the current environment, as we all know, the new tariff rates and trade wars are the biggest and most significant catalysts for takeover rumors. However, hedge funds also take note of other factors when anticipating a takeover. For instance, the Federal Reserve cut interest rates. After a series of cuts that started in September, the Fed has paused the interest rate adjustments and maintained them between 4.25% and 4.50% since December 2024. The range is not historically low, compared to the near 0% interest rates the Fed announced amid the COVID-19 pandemic. However, larger companies may find it easier and less expensive to fund an acquisition or merger at the current interest levels. On the other hand, the broader market sentiment could also play a vital role in takeover rumors. The expected takeover might get rescheduled or withdrawn, depending on the favorability of the market sentiment. For instance, the recent falls in the stock market might reflect negatively on the market sentiment, discouraging companies from risking an acquisition or takeover. Meanwhile, with their keen insights, hedge funds attempt to identify undervalued assets and potential takeover candidates. In addition to reflecting confidence in market resilience, their actions signify the importance of timely and informed decision-making. We have put together our list by following a specific and straightforward methodology. Primarily, we have identified stocks with takeover rumors that have started or advanced in the past year. All the data used in this regard was taken from financial news, databases, and analyst reports, with all information updated as of April 21, 2025. This criterion is in place to ensure the relevance of the rumor with the hedge fund holdings for a stock. We have also collected information on the hedge fund holdings as of April 21, 2025, from the Insider Monkey database of Q4 2024. Based on this data, we have ranked our picks from 20 to 1, with 20 being the stock with the least number of hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). An independent distributor in their pharmacy with a range of biopharmaceutical products on in New Jersey, a biopharmaceutical company, ADMA Biologics, Inc. (NASDAQ:ADMA) specializes in developing and commercializing plasma-derived biologics. These are used to treat and prevent infectious diseases in immunocompromised patients. The company's flagship products include ASCENIV and BIVIGAM. It emphasizes FDA-approved production capabilities and expansion of its plasma collection network to compete with other players. With clinical efficiency, the company addresses critical gaps in immune globulin therapy. After acquiring a high level of the company's stake (5.6%) by activist investors Caligan Partners in February 2022, ADMA Biologics, Inc. (NASDAQ:ADMA) has been the subject of takeover rumors. Caligan Partners, after acquiring the stake, has reportedly urged the company to consider a potential sale through a strategic review. Accordingly, in the recent quarters, many concerns have been raised with respect to the company's financial reporting, including the resignation of its independent outside auditor, CohnReznick LLP. However, the matter was subsequently settled with Kirby McInerney LLP. Significant shareholder activities and the recently emerging concerns could lead to potential takeovers by pharmaceutical or biotech companies. We noted a total of 37 hedge funds taking positions in ADMA Biologics, Inc. (NASDAQ:ADMA), as per Insider Monkey's Q4 2024 database. It points to a fair degree of institutional confidence, likely partly driven by the circulating takeover rumors. Overall, ADMA ranks 13th on our list of takeover rumor stocks hedge funds are buying. While we acknowledge the potential of ADMA, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks have lost around 25%. If you are looking for an AI stock that is more promising than ADMA but trades at less than 5 times its earnings, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
